GenSight Biologics S.A. (LON: 0RIM)

Market Cap	28.76M
Revenue (ttm)	1.68M
Net Income (ttm)	-17.05M
Shares Out	n/a
EPS (ttm)	-0.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,442
Average Volume	3,885
Open	0.286
Previous Close	0.292
Day's Range	0.275 - 0.286
52-Week Range	0.202 - 0.495
Beta	2.33
RSI	43.95
Earnings Date	Jan 22, 2025

About GenSight Biologics

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated N...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 16
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RIM

Financial Performance

In 2023, GenSight Biologics's revenue was 2.96 million, a decrease of -39.08% compared to the previous year's 4.87 million. Losses were -26.22 million, -5.09% less than in 2022.

Financial numbers in EUR